15 terminated. 15 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Terminated 15 |
| Phase 1 | 3 | Terminated 3 |
| Phase 3 | 3 | Terminated 3 |
Follow Malaria: new trials by email Literature Review of Malaria trials Research Report on Malaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults R21/Matrix-M, ChAd63/MVA ME-TRAP, intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge - Malaria,Falciparum | Phase 2 | Terminated | University of Oxford | 80 | 2022-08-31 | 2025-02-20 |
| Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria artemether:lumefantrine (2.5 mg:30 mg) - Plasmodium Falciparum Malaria | Phase 2 / Phase 3 | Terminated | Novartis Pharmaceuticals | 28 | 2020-12-21 | 2026-01-13 |
| MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria MMV390048 - Malaria | Phase 2 | Terminated | Medicines for Malaria Venture | 8 | 2017-10-20 | 2021-12-09 |
| Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient, Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient, Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient - Malaria | Phase 2 / Phase 3 | Terminated | London School of Hygiene and Tropical Medicine | 61 | 2015-12-01 | 2016-09-09 |
| A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection DSM265, OZ439 - Malaria | Phase 1 / Phase 2 | Terminated | Medicines for Malaria Venture | 16 | 2015-10-01 | 2020-06-05 |
| Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria Eurartesim tablets - Malaria, Vivax | Phase 2 | Terminated | Alfasigma S.p.A. | 27 | 2014-06-18 | 2018-09-17 |
| Anti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated Malaria SAR97276A, arthemeter + lumefantrine (ACTs) - Malaria | Phase 2 | Terminated | Sanofi | 20 | 2011-10-01 | 2012-12-13 |
| Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria Sevuparin sodium + atovaquone/proquanil, atovaquone/proquanil - Malaria, Falciparum | Phase 1 / Phase 2 | Terminated | Modus Therapeutics AB | 53 | 2011-09-01 | 2014-08-19 |
| Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine p52-/p36- GAP Vaccine, p52-p36- GAP Vaccine - Malaria | Phase 1 / Phase 2 | Terminated | Seattle Children's Hospital | 6 | 2010-03-01 | 2019-10-28 |
| Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children. SAR97276A - Malaria | Phase 2 | Terminated | Sanofi | 113 | 2008-08-01 | 2010-06-16 |
| Azithromycin in Combination With Chloroquine Versus Chloroquine in the Eradication of Asymptomatic Plasmodium Falciparum Azithromycin/Chloroquine, Chloroquine - Malaria, Falciparum | Phase 2 | Terminated | Pfizer | 14 | 2004-08-01 | 2011-04-26 |
| Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia Azithromycin/Chloroquine, Sulfadoxine-Pyrimethamine/Chloroquine - Malaria, Falciparum | Phase 2 / Phase 3 | Terminated | Pfizer | 32 | 2004-03-01 | 2008-11-03 |
| Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults Tafenoquine, Chloroquine + Primaquine, tafenoquine - Malaria, Plasmodium Vivax | Phase 2 | Terminated | U.S. Army Medical Research and Development Command | 70 | 2003-09-15 | 2018-02-23 |
| Pentoxifylline in Children With Malaria Pentoxifylline - Plasmodium Falciparum Malaria | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 50 | 2002-01-01 | 2010-08-27 |
| Cotrifazid Safety and Efficacy Against Malaria Cotrifazid vs mefloquine or quinine+SP - Clinical Malaria | Phase 2 | Terminated | Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland | 330 | 2000-04-01 | 2006-05-08 |
Malaria, Falciparum (7) · Malaria, Vivax (2) · Lymphoma, Follicular (1)
Infections (15) · Mosquito-Borne Diseases (15) · Parasitic Diseases (15) · Protozoan Infections (15) · Vector Borne Diseases (15) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Chloroquine (3) · Azithromycin (2) · Atovaquone (1) · DSM265 (1) · Injections, Intradermal (1) · Lumefantrine (1) · MMV390048 (1) · Pentoxifylline (1) · Primaquine (1) · artefenomel (1) · artenimol (1) · fanasil, pyrimethamine drug combination (1) · piperaquine (1) · tafenoquine (1)
Medicines for Malaria Venture (2) · Pfizer (2) · Sanofi (2) · Alfasigma S.p.A. (1) · Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland (1) · London School of Hygiene and Tropical Medicine (1) · Modus Therapeutics AB (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis Pharmaceuticals (1) · Seattle Children's Hospital (1) · U.S. Army Medical Research and Development Command (1) · University of Oxford (1)
Burkina Faso (3) · Kenya (3) · Benin (2) · Gabon (2) · Thailand (2) · Australia (1) · Democratic Republic of the Congo (1) · Ethiopia (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Netherlands (1) · Papua New Guinea (1) · Spain (1)
Anna Leitgeb, PhD (1) · Blaise Genton, MD, PhD (1) · Christoph Hatz, Prof Dr Med (1) · Esayas Gudina, MD (1) · James McCarthy, Prof (1) · Mezgebu Silamsaw, MD (1) · Michele Spring, M.D. (1) · Sornchai Looaree Suwan, MD (1)
PMID 28472957, PMID 24029408, PMID 29121061, PMID 29244851, PMID 29324864, PMID 30269312, PMID 30858218, PMID 32479608, PMID 34179977, PMID 36509063, PMID 41199347, PMID 41495411